利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

128 条记录 (耗时 0.035 秒)

    REOVIRUSES HAVING MODIFIED SEQUENCES
    23.
    发明申请
    REOVIRUSES HAVING MODIFIED SEQUENCES 审中-公开
    具有修改序列的病毒

    公开(公告)号：US20140186301A1

    公开(公告)日：2014-07-03

    申请号：US14179840

    申请日：2014-02-13

    申请人： Oncolytics Biotech Inc.

    发明人： Matthew C. Coffey

    IPC分类号： C12N7/00 ,  A61K45/06 ,  A61K35/76

    CPC分类号： A61K45/06 ,  A61K35/13 ,  A61K35/765 ,  C07K14/005 ,  C12N7/00 ,  C12N2720/12221 ,  C12N2720/12222

    摘要： The invention provides for modified reovirus nucleic acid sequences and modified reovirus polypeptide sequences as well as reoviruses containing such modified nucleic acid or polypeptide sequences. The invention also provides for pharmaceutical compositions that include reoviruses having a modified sequence as well as methods of making and using such reoviruses.

    摘要翻译： 本发明提供了修饰的呼肠孤病毒核酸序列和修饰的呼肠孤病毒多肽序列以及含有这种修饰的核酸或多肽序列的呼肠病毒。 本发明还提供了包含具有修饰序列的呼肠病毒的药物组合物以及制备和使用这些呼肠孤病毒的方法。

    LIQUID VIRAL FORMULATIONS
    25.
    发明申请
    LIQUID VIRAL FORMULATIONS 有权
    液体病毒制剂

    公开(公告)号：US20120141421A1

    公开(公告)日：2012-06-07

    申请号：US13309966

    申请日：2011-12-02

    申请人： Matthew C. Coffey ,  Sarah Serl ,  Leo Pavliv

    发明人： Matthew C. Coffey ,  Sarah Serl ,  Leo Pavliv

    IPC分类号： A61K35/76 ,  A61P35/00

    CPC分类号： A61K35/765 ,  A61K35/76 ,  A61K39/15 ,  A61K2039/525 ,  C12N7/00 ,  C12N2720/12051 ,  C12N2720/12211 ,  C12N2720/12232 ,  C12N2720/12251

    摘要： Provided herein are liquid viral formulations useful for the stabilization and storage of viruses and methods of preparing these formulations. The liquid viral formulations described herein include a virus (e.g., a purified virus) and a non-viral composition including excipients and a liquid carrier. The formulations can be used, for example, to retain the infectivity or immunogenicity of viruses during periods of storage.

    摘要翻译： 本文提供了可用于稳定和储存病毒的液体病毒制剂和制备这些制剂的方法。 本文所述的液体病毒制剂包括病毒（例如，纯化病毒）和包含赋形剂和液体载体的非病毒组合物。 该制剂可以用于例如在储存期间保留病毒的感染性或免疫原性。

    Reovirus for the treatment of cellular proliferative disorders
    26.
    发明授权
    Reovirus for the treatment of cellular proliferative disorders 有权

    公开(公告)号：US08071087B2

    公开(公告)日：2011-12-06

    申请号：US12841550

    申请日：2010-07-22

    申请人： Patrick W. K. Lee ,  James Strong ,  Matthew C. Coffey

    发明人： Patrick W. K. Lee ,  James Strong ,  Matthew C. Coffey

    IPC分类号： A61K39/15 ,  A61K48/00

    CPC分类号： A61K9/0019 ,  A61K35/765 ,  C12N2720/12032 ,  C12N2720/12232

    摘要： Methods for treating proliferative disorders, by administering reovirus to a Ras-mediated proliferative disorder, are disclosed. The reovirus is administered so that it ultimately directly contacts ras-mediated proliferating cells. Proliferative disorders include but are not limited to neoplasms. Human reovirus, non-human mammalian reovirus, and/or avian reovirus can be used. If the reovirus is human reovirus, serotype 1 (e.g., strain Lang), serotype 2 (e.g., strain Jones), serotype 3 (e.g., strain Dearing or strain Abney), as well as other serotypes or strains of reovirus can be used. Combinations of more than one type and/or strain of reovirus can be used, as can reovirus from different species of animal. Either solid neoplasms or hematopoietic neoplasms can be treated.

    Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders
    29.
    发明授权
    Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders 失效
    用于预防呼肠孤病毒识别用于治疗细胞增殖性疾病的方法

    公开(公告)号：US07708987B2

    公开(公告)日：2010-05-04

    申请号：US11809195

    申请日：2007-05-30

    申请人： Matthew C. Coffey ,  Bradley G. Thompson

    发明人： Matthew C. Coffey ,  Bradley G. Thompson

    IPC分类号： A61K48/00 ,  A61K39/15 ,  A61K39/42 ,  C12N7/04

    CPC分类号： A61K35/765 ,  A61K38/13 ,  C07K16/081 ,  C07K16/10 ,  C07K16/4216 ,  C12N9/1205 ,  C12N2720/12232 ,  Y10S435/948 ,  Y10S435/975 ,  A61K2300/00

    摘要： The present invention pertains to methods for preventing reovirus recognition in the treatment of cellular proliferative disorders, and particularly ras-mediated cellular proliferative disorders, in mammals. The mammal may be selected from dogs, cats, sheep, goats, cattle, horses, pigs, mice, humans and non-human primates. The method comprises suppressing or otherwise inhibiting the immune system of the mammal and, concurrently or subsequently, administering to the proliferating cells an effective amount of one or more reoviruses under conditions which result in substantial lysis of the proliferating cells. In particular, the methods provide for reovirus treatment of immunosuppressed or immuno-deficient mammals to treat the proliferative disorders. Immunosuppression, immunoinhibition or otherwise inducing an immunodeficient state in a mammal renders the reovirus more effective. The methods may include the selective removal of immune constituents that may interfere with the systemic delivery of the virus; preventing reovirus recognition by the host immune system; and removal of the virus from an immune suppressed or immune incompetent host following treatment with reovirus. Alternatively, reovirus may be administered to a mammal with a diminished immune response system under conditions which result in substantial lysis of the proliferating cells. Immune systems may be compromised by one or more of the following: an HIV infection; as a side effect of chemotherapy or radiation therapy; by selective removal of B and/or T cell populations; by removal of antibodies (anti-antireovirus antibodies or all antibodies), and the like.

    摘要翻译： 本发明涉及在哺乳动物中治疗细胞增殖性疾病，特别是ras介导的细胞增殖性疾病中预防呼肠孤病毒识别的方法。 哺乳动物可以选自狗，猫，绵羊，山羊，牛，马，猪，小鼠，人和非人灵长类动物。 该方法包括抑制或以其他方式抑制哺乳动物的免疫系统，并且同时或随后在导致增殖细胞的实质性裂解的条件下向增殖细胞施用有效量的一种或多种呼吸道病毒。 特别地，该方法提供了呼肠孤病毒治疗免疫抑制或免疫缺陷型哺乳动物以治疗增殖性疾病。 在哺乳动物中的免疫抑制，免疫抑制或其他诱导免疫缺陷状态使呼肠孤病毒更有效。 所述方法可以包括选择性去除可能干扰病毒的全身递送的免疫组分; 预防宿主免疫系统的呼肠孤病毒识别; 并在用呼肠孤病毒治疗后从免疫抑制或免疫不称职的宿主中除去病毒。 或者，呼肠孤病毒可以在导致增殖细胞的实质性裂解的条件下给予具有减少的免疫应答系统的哺乳动物。 免疫系统可能受到以下一种或多种感染：HIV感染; 作为化疗或放射治疗的副作用; 通过选择性去除B和/或T细胞群体; 通过除去抗体（抗 - 抗病毒抗体或全部抗体）等。

    Reovirus for the Treatment of Cellular Proliferative Disorders
    30.
    发明申请
    Reovirus for the Treatment of Cellular Proliferative Disorders 有权
    呼肠孤病毒治疗细胞增生性疾病

    公开(公告)号：US20090117082A1

    公开(公告)日：2009-05-07

    申请号：US12323223

    申请日：2008-11-25

    申请人： Patrick W.K. Lee ,  James Strong ,  Matthew C. Coffey

    发明人： Patrick W.K. Lee ,  James Strong ,  Matthew C. Coffey

    IPC分类号： A61K35/76

    CPC分类号： A61K9/0019 ,  A61K35/765 ,  C12N2720/12032 ,  C12N2720/12232

    摘要： Methods for treating proliferative disorders, by administering reovirus to a Ras-mediated proliferative disorder, are disclosed. The reovirus is administered so that it ultimately directly contacts ras-mediated proliferating cells. Proliferative disorders include but are not limited to neoplasms. Human reovirus, non-human mammalian reovirus, and/or avian reovirus can be used. If the reovirus is human reovirus, serotype 1 (e.g., strain Lang), serotype 2 (e.g., strain Jones), serotype 3 (e.g., strain Dearing or strain Abney), as well as other serotypes or strains of reovirus can be used. Combinations of more than one type and/or strain of reovirus can be used, as can reovirus from different species of animal. Either solid neoplasms or hematopoietic neoplasms can be treated.

    摘要翻译： 公开了通过向Ras介导的增殖性病症施用呼肠孤病毒来治疗增殖性疾病的方法。 施用呼肠孤病毒使其最终直接接触ras介导的增殖细胞。 增生性疾病包括但不限于赘生物。 可以使用人呼肠病毒，非人哺乳动物呼肠病毒和/或禽呼肠孤病毒。 如果呼肠孤病毒是人呼肠病毒，则可以使用血清型1（例如，菌株Lang），血清型2（例如菌株琼斯），血清型3（例如，菌株Dearing或菌株Abney）以及呼肠孤病毒的其它血清型或菌株。 可以使用多于一种类型和/或菌株的呼肠病病毒的组合，以及来自不同动物种类的呼肠弧病毒。 可以治疗实体肿瘤或造血赘生物。